Johnson & Johnson announced a voluntary most‑favored‑nation (MFN) pricing agreement with the White House aimed at improving U.S. drug access, leaving AbbVie and Regeneron as the only major firms yet to finalize terms. The deal follows the administration’s MFN initiative and shifts pricing negotiations for branded medicines. Separately, Genentech said its switch from a large drug benefit plan to a privately held entity will save the Roche subsidiary about $70 million, according to CEO Ashley Magargee. Both moves show companies adapting commercial strategies to new pricing pressures and policy levers. The actions will influence payer contracting, manufacturer margins and patient access—and could prompt further voluntary pricing deals or structural changes in how pharma manages benefits.